ArticleInternational journal of clinical and experimental pathology2014
PNMA1 promotes cell growth in human pancreatic ductal adenocarcinoma.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- PNMA1 mediates melphalam chemoresistance in retinoblastoma via promoting DNA repair.Scientific reports · 2025Article
- Ribosomal profiling of human endogenous retroviruses in healthy tissues.BMC genomics · 2024Review
- Evolutionary paths to mammalian longevity through the lens of gene expression.The EMBO journal · 2023Article
- Large-scale across species transcriptomic analysis identifies genetic selection signatures associated with longevity in mammals.The EMBO journal · 2023Article
- lncRNA JPX modulates malignant progress of osteosarcoma through targeting miR-33a-5p and PNMA1 regulatory loop.Translational oncology · 2022Article
- Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review.International journal of molecular sciences · 2022Review
- Article
- Transcriptome‑wide piRNA profiling in human gastric cancer.Oncology reports · 2019Article
- DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma.Journal of immunology research · 2019Article
- Tsoong induces apoptosis and inhibits proliferation, migration and invasion of pancreatic ductal adenocarcinoma cells.Molecular medicine reports · 2018Article
- Pnma5 is essential to the progression of meiosis in mouse oocytes through a chain of phosphorylation.Oncotarget · 2017Article
- CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib.Scientific reports · 2016Article
- Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.Oncotarget · 2016Article
- High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2015Article
- Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma.Scientific reports · 2015Article
- CHRM3 is a novel prognostic factor of poor prognosis in patients with endometrial carcinoma.American journal of translational research · 2015Article
- Alteration in PNMA1 expression is associated with poor prognosis and tumor immune infiltration in head and neck squamous cell carcinoma.Journal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraneoplastic Ma1 (PNMA1) is a member of an expanding family of 'brain/testis' proteins involved in an autoimmune disorder defined as paraneoplastic neurological syndrome (PNS). Although it is widely studied in PNS, little is known about the underlying clinical significance and biological function of PNMA1 in tumors. Here, we find that elevated PNMA1 expression is more commonly observed in pancreatic ductal adenocarcinoma (PDAC) cell lines, compared with normal pancreatic cell and tissues from pancreatic ductal adenocarcinoma patient. Besides, higher PNMA1 expression is closely correlated with large tumor size. Suppression of endogenous PNMA1 expression decreases cell viability and promotes cell apoptosis. Subsequent studies reveal that the PI3K/AKT, MAPK/ERK pathway and members of the anti-apoptotic Bcl-2 family may be involved in the pro-survival and anti-apoptotic effect of PNMA1 on PDAC. Taken together, this study provides evidence that PNMA1 is involved in tumor growth of pancreatic carcinoma and PNMA1-related pathways might represent a new treatment strategy.
Indexed as
Identifiers
25120759PMC4128994W2236640083What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.